Mesoblast Stock News

Mesoblast Limited (NASDAQ: MESO) refinanced its existing senior debt facility with a new $90 million five-year facility provided by Oaktree Capital Management LP. Mesoblast drew the first tranche

22 Nov 2021 - A snapshot of the stocks on the move, featuring Meridian Energy (ASX:MEZ), AMP (ASXAMP), Mesoblast (ASX:MSB).

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (Oaktree).

What''s happened to the company''s shares? The post Mesoblast (ASX:MSB) share price tumbles 8% giving back most of yesterdays gains appeared first on The Motley Fool Australia .

These ASX shares are out of form The post Why Best & Less, BHP, Mesoblast, and Nearmap shares are falling appeared first on The Motley Fool Australia .

The ASX’s big biotechs, particular Mesoblast (ASX:MSB), have had intriguing years in 2021, but there could be more to look … Read More The post Mesoblast and the ASX’s other big biotechs have intrigued investors this year; here’s what’s in store next appeared first on Stockhead .

Mesoblast (NASDAQ:MESO) and Advanced Life Sciences (OTCMKTS:ADLS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Ratings This is a breakdown of current recommendations and price targets for Mesoblast and Advanced []

Mesoblast Limited (NASDAQ: MESO ) presented new results from the landmark Phase 3 study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Data were shared at the American Heart Association annual Scientific Sessions. A single dose of rexlemestrocel-L on top of standard of care reduced the incidence of heart attacks or strokes by 65% Full story available on Benzinga.com

The S&P/ASX 200 Index firmed 0.4 per cent on Monday as Mesoblast shares rallied 11.8 per cent on positive results for a key therapy treating heart failure.

Drug developer Mesoblast (ASX:MSB) has spiked on the ASX today after announcing findings from a third-phase trial for its rexlemestrocel-L product in chronic heart failure.

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index Read More The post ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure appeared first on Stockhead .

Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation NEW YORK, Nov. 14, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF) were presented as a late breaking presentation at the American Heart Association (AHA) annual Scientific Sessions during a featured program titled Building on the Foundations of Treatment: Advances in Heart Failure Therapy''. The trial''s co-principal investigator Dr. Emerson Perin, Medical Director of Texas Heart Institute, and Clinical Professor, Baylor College of Medicine, presented new results from the landmark study showing a significant relationship between presence of systemic inflammation as quantified by high-sensitivity C-reactive protein (hs-CRP) and treatment benefit with rexlemestrocel-L on risk of cardiovascular mortality, heart attacks or strokes.

It''s been a very good day for Mesoblast shares The post Mesoblast (ASX:MSB) share price surges 9% higher on trial update appeared first on The Motley Fool Australia .

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the ra

Mesoblast Limited (NASDAQ: MESO) shares dived on Tuesday as the FDA raised more questions around its flagship drug candidate, and its annual loss widened.  What Happened: In the June quarter, Mes